Development and distribution of products primarily, but not exclusively, in medical technology for the diagnosis and therapy of neurodegenerative, mental and new neurological diseases with a broad spectrum of symptoms using methods of sensory and electrical neuromodulation, especially “artificial intelligence” (AI) methods.

These include:

  • Alzheimer's disease (AD)
  • Parkinson's disease (PD)
  • the post-COVID neurological syndrome (also “Long COVID” - PCNS)
  • Major depressive disorder (MDD), including chronic depression.